Zacks Investment Research upgraded shares of Innoviva (NASDAQ:INVA) from a hold rating to a buy rating in a research report report published on Tuesday morning. They currently have $18.00 price target on the biotechnology company’s stock.
According to Zacks, “Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company’s portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. “
Several other brokerages have also recently commented on INVA. Stifel Nicolaus reissued a hold rating and issued a $17.00 price target on shares of Innoviva in a research note on Friday, February 9th. BidaskClub raised Innoviva from a buy rating to a strong-buy rating in a research note on Saturday, March 24th. TheStreet raised Innoviva from a c+ rating to a b rating in a research note on Friday, February 9th. Finally, ValuEngine raised Innoviva from a hold rating to a buy rating in a research note on Wednesday, March 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $14.17.
Shares of NASDAQ INVA opened at $15.97 on Tuesday. The company has a market capitalization of $1,643.44, a P/E ratio of 13.65 and a beta of 2.17. Innoviva has a 52 week low of $11.02 and a 52 week high of $17.99. The company has a debt-to-equity ratio of -2.37, a current ratio of 5.77 and a quick ratio of 5.77.
Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Thursday, February 8th. The biotechnology company reported $0.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The business had revenue of $69.52 million during the quarter, compared to analysts’ expectations of $67.41 million. Innoviva had a negative return on equity of 48.93% and a net margin of 61.76%. The firm’s quarterly revenue was up 59.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.22 EPS. equities analysts forecast that Innoviva will post 2.26 earnings per share for the current year.
In other Innoviva news, insider Eric Desparbes sold 5,378 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $16.52, for a total transaction of $88,844.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP George B. Abercrombie sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The stock was sold at an average price of $16.51, for a total value of $132,080.00. The disclosure for this sale can be found here. 1.44% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new stake in Innoviva during the third quarter worth approximately $144,000. Macquarie Group Ltd. bought a new stake in Innoviva during the third quarter worth approximately $144,000. Meadow Creek Investment Management LLC boosted its position in Innoviva by 30.0% during the fourth quarter. Meadow Creek Investment Management LLC now owns 14,084 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 3,248 shares during the period. Xact Kapitalforvaltning AB bought a new stake in Innoviva during the fourth quarter worth approximately $201,000. Finally, Caxton Associates LP bought a new stake in Innoviva during the fourth quarter worth approximately $256,000. 75.04% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/18/innoviva-inva-raised-to-buy-at-zacks-investment-research.html.
Innoviva Company Profile
Innoviva, Inc engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI); ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI); and TRELEGY ELLIPTA (the combination FF/UMEC/VI).
Get a free copy of the Zacks research report on Innoviva (INVA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.